Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
2000 Turkeys
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
2000 Turkeys
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
China Gas Holdings Ltd
SOS Limited Class A Ordinary Shares
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Akebia Therapeutics, Inc. - Common Stock
(NQ:
AKBA
)
0.5737
+0.0319 (+5.89%)
Delayed Quote
Updated: 4:00 PM EST, Nov 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Akebia Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
September 23, 2022
Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000...
Via
TheNewswire.com
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
↗
September 22, 2022
Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000...
Via
Benzinga
Akebia Therapeutics Return On Capital Employed Insights
↗
August 16, 2022
Via
Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
↗
August 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
↗
August 05, 2022
Via
Benzinga
Akebia Therapeutics: Q2 Earnings Insights
↗
August 04, 2022
Akebia Therapeutics (NASDAQ:AKBA) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Why Amazon Is Trading Higher By 12%: Here Are 23 Stocks Moving Premarket
↗
July 29, 2022
Gainers Getty Images Holdings, Inc. (NYSE: GETY) rose 104.5% to $21.47 in pre-market trading.
Via
Benzinga
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
↗
July 05, 2022
Gainers Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64. Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday.
Via
Benzinga
REV Stock Moves Amid Revlon Bankruptcy, Short Squeeze Hopes
↗
July 01, 2022
Revlon (REV) stock is on the move Friday as the volatility surrounding the meme stock continues following its bankruptcy announcement.
Via
InvestorPlace
U.S Stocks Turn Lower; Dow Tumbles Over 100 Points
↗
July 01, 2022
U.S. stocks turned lower midway through trading, with the Dow Jones dropping more than 100 points on Friday.
Via
Benzinga
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
↗
July 01, 2022
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday.
Via
Benzinga
Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today?
↗
July 01, 2022
Akebia Therapeutics (AKBA) stock is taking off on Friday after the kidney treatment company revealed the return of rights for vadadustat.
Via
InvestorPlace
Why U.S. Stocks Are Trading Higher, Manufacturing Report And More
↗
July 01, 2022
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday.
Via
Benzinga
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
↗
July 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
July 01, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
↗
July 01, 2022
Good morning, trader! It's time for another look at the biggest pre-market stock movers as we dive into the latest news for Friday!
Via
InvestorPlace
Akebia Therapeutics And 20 Stocks Moving Premarket
↗
July 01, 2022
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 83.2% to $0.8250 in pre-market trading after dropping 10% on Thursday.
Via
Benzinga
Micron, Akebia Therapeutics And 3 Stocks To Watch Heading Into Friday
↗
July 01, 2022
Some of the stocks that may grab investor focus today are:
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
June 30, 2022
Gainers
Via
Benzinga
Why Akebia Therapeutics Stock Is Soaring After Hours
↗
June 30, 2022
Akebia Therapeutics Inc (NASDAQ: AKBA) shares are surging in Thursday's after-hours session after the company executed an agreement to terminate its Vadadustat collaboration and license agreements with...
Via
Benzinga
Aspen Aerogels And 28 Stocks Moving Premarket
↗
June 30, 2022
Gainers
Via
Benzinga
Akebia Therapeutics (AKBA) Stock Soars 18% Despite Lack of News
↗
June 29, 2022
AKBA stock is up big, but the lack of news is concerning considering that Akebia Therapeutics already faces a regulatory setback.
Via
InvestorPlace
Why Is Allena Pharmaceuticals Jumping By 207%? 45 Stocks Moving In Wednesday's Mid-Day Session
↗
June 29, 2022
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 207% to $0.3650 after the company announced it has terminated its previously announced at-the-market offering.
Via
Benzinga
This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
↗
June 30, 2022
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
June 29, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
June 29, 2022
Good morning, trader! With the start of another day comes our breakdown of the biggest pre-market stock movers for Wednesday!
Via
InvestorPlace
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Long Term Investor Alert: Investigation of Potential Wrongdoing
↗
June 20, 2022
San Diego, CA -- (SBWIRE) -- 06/20/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Akebia Therapeutics, Inc..
Via
SBWire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
June 15, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
June 15, 2022
It's time for another breakdown of the biggest pre-market stock movers as we get ready for the opening bell on Wednesday!
Via
InvestorPlace
18 Stocks Moving in Thursday's Pre-Market Session
↗
June 09, 2022
Gainers View, Inc. (NASDAQ: VIEW) rose 18.5% to $2.05 in pre-market trading after declining 5% on Wednesday.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today